Nagi Reddy Seelam's most recent trade in Concord Drugs Ltd. was a Acquisition of 84,145 Equity Shares done at an average price of Rs. 25.0 . Disclosure was reported to the exchange on March 4, 2021 under the SEBI (Prohibition of Insider Trading) Regulations, 2015.
Nagi Reddy Seelam's has made SAST transactions in Concord Drugs Ltd. recently where a Acquisition of 44,359 shares done . Disclosure was reported to the exchange on Sept. 24, 2021.
Stock | Client Name | Client Category | Action* | Reported To/By Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Period | Regulation (Insider/SAST) | Security Type | Mode |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Concord Drugs | Nagi Reddy Seelam | Promoter | Acquisition | 25 Sep 2021 | 44,359 | 1,886,899 (21.58%) | 0.51% | - | 24 Aug 2021 24 Sep 2021 |
SAST (29(2)) | - | Market | |
Concord Drugs | Nagi Reddy Seelam | Promoter & Director | Acquisition | 04 Mar 2021 | 84,145 | 1,842,540 (21.07%) | 0.96% | 25.0 | 2,103,295 | 02 Mar 2021 03 Mar 2021 |
Insider Trading | Equity Shares | Market Purchase |
Concord Drugs | Nagi Reddy Seelam | Promoter | Acquisition | 06 Mar 2021 | 84,145 | 1,842,540 (21.07%) | 0.96% | - | 02 Mar 2021 03 Mar 2021 |
SAST (29(2)) | - | Market | |
Concord Drugs | Nagi Reddy Seelam | Promoter | Acquisition | 02 Mar 2021 | 55,395 | 1,758,395 (20.11%) | 0.63% | 25.0 | 1,384,729 | 25 Feb 2021 01 Mar 2021 |
Insider Trading | Equity Shares | Market Purchase |
Concord Drugs | Nagi Reddy Seelam | Promoter | Acquisition | 03 Mar 2021 | 55,395 | 1,758,395 (20.11%) | 0.63% | - | 25 Feb 2021 01 Mar 2021 |
SAST (29(2)) | - | Market |